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Bile acid malabsorption (BAM) causing chronic diarrhea may be due to organic as well as functional disorders, and some of them
were included under the general label of diarrheic-type irritable bowel syndrome (IBS-D). The 75-selenium homocholic acid
taurine (SeHCAT) test is a nuclear medicine investigation considered to be the gold standard for the diagnosis of bile acid
malabsorption (BAM). Many studies demonstrate that it could be eﬀective in the clinical workout of chronic diarrhea due to
diﬀerent conditions. The SeHCAT test provides a quantitative assessment to estimate the severity of BAM and the possible
response to therapy with bile acid sequestrants (BASs). However, there is no general agreement regarding its cutoﬀ value and
the test is not widely available. The aim of this review is to discuss the advantages and disadvantages of the SeHCAT test in
clinical practice.
1. Introduction
Bile acid diarrhea (BAD) is caused by bile acid malabsorption
(BAM). It is characterised by watery diarrhea (often
postprandial), bloating, urge for defecation, and faecal incon-
tinence at times.
BAM may occur in many diﬀerent pathological condi-
tions, which sometimes overlap (Figure 1). It is estimated
that about 1% of the general population is aﬀected by BAD
[1]. BAM is often caused by a surgical resection or a struc-
tural impairment of the ileum (i.e., Crohn’s disease (CD)),
but many studies [2] demonstrate the presence of BAM in
patients with predominant irritable bowel syndrome
diarrhea (IBS-D) or with functional diarrhea (FD).
Clinically, BAM is classiﬁed as follows [3]: type 1: ileal
dysfunction/resection (Crohn’s disease); type 2: primary or
idiopathic, characterised by watery diarrhea with (IBS) or
without (FD) pain responding to bile acid sequestrant drugs
(BASs); type 3: associated with other gastrointestinal disor-
ders such as coeliac disease, small intestinal bacterial
overgrowth (SIBO), and chronic pancreatitis; and type 4:
due to an impaired FGF-19 feedback inhibition that causes
excessive BA synthesis [4].
Currently available therapies are BASs like cholestyr-
amine, colestipol, and colesevelam. Obeticholic acid could
be a promising drug for BAM: it is an agonist of the farnesoid
X receptor (FXR), which increases ﬁbroblastic growth factor
19 (FGF-19) synthesis and decreases bile acid (BA) synthesis
by hepatocytes [3, 5].
2. Pathophysiology
BAs excreted into the intestinal lumen are mainly reabsorbed
in the ileum by a speciﬁc receptor, the apical sodium-
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dependent bile acid transporter (ASBT), and return to the
liver via the portal venous system (Figure 2).
BAs entering the enterohepatic circulation are primary
acids synthesised from cholesterol in the hepatocytes. They
are actively secreted across the canalicular membrane and
carried into the bile to the gallbladder, where they are con-
centrated in the fasting state. In a single pass of clearance,
about 95% of BAs are actively absorbed from the lumen of
the terminal ileum, leaving only approximately 5% in the
colon, where a fraction is passively reabsorbed after some
modiﬁcations including deconjugation and oxidation of
hydroxyl groups [6]; hydrolysis and hydroxyl group dehy-
drogenation reactions are performed by a broad spectrum
of intestinal bacteria [7].
BAM can occur due to genetic mutations of the ASBT
receptor, which is the ileal transporter involved in the
reabsorption of BAs [8]. Also, genetic mutations of TGR5, a
G-protein-coupled receptor that functions as a cell surface
receptor for BAs and regulates basal and cholinergic-
induced secretion in the colon and colonic transit, can
predispose to BAM [9]. Another important cause of BAM
may be a deﬁciency in FGF-19, a hormone produced in the
enterocytes that regulates hepatic BA synthesis via a negative
feedback mechanism [4, 10]. Walters et al. reported lower
serum FGF-19 in patients with BAM and an inverse relation-
ship between FGF-19 and serum C4 (a surrogate index of
hepatic BA synthesis) [4]. Genetic variations in the proteins
involved in the feedback regulation of BA synthesis, speciﬁ-
cally the klothoB gene and ﬁbroblast growth factor 4 gene
(Figure 2), are rare causes of BAM. A signiﬁcant association
of SNP rs17618244 in the klothoB (KLB) gene with colonic
transit in IBS-D has been demonstrated [11]. An accelerated
small-bowel transit, bypassing active BA transport in the
ileum, has been hypothesised as a cause of BAM in idiopathic
[12] and postradiation cases [13].
3. Diagnosis
The diagnosis of BAM can be obtained using (1) 14C-
glycocholate breath and stool test, (2) determination of
serum C4 (7α-hydroxy-4 cholesten-3-one) or FGF-19 levels,
(3) 24-hour faecal BA output dosage, and (4) 75-selenium
homocholic acid taurine (SeHCAT) test.
The 14C-glycocholate breath and stool test has a lim-
ited clinical use because it is cumbersome and time-
consuming [14, 15].
Determination of serum C4 levels using a relatively
simple chromatographic method is potentially applicable to
most patients, but it requires further clinical validation. It
varies according to a circadian rhythm, and false-positive
results are reported in patients with liver disease or in those
treated with statins. The method has a speciﬁcity and sensi-
tivity of 90% and 77%, respectively, for BAM type 1 and
97% and 74%, respectively, for BAM type 2 [16].
Serum FGF-19 levels measured using ELISA are inversely
related to C4. Recent data show that FD and IBS-D are
associated with increased serum C4 levels and total faecal
BAs and with decreased serum FGF-19 levels [17].
The assessment of the 24-hour faecal output of BAs is
cumbersome and not widely available. An enzymatic assay
indirectly measures faecal BAs, but it tends to underestimate
total BAs [18]. Moreover, when it is used to measure BA
concentrations in small-bowel ﬂuid or in ileostomy eﬄuent,
it is not reliable [19].
A possible diagnostic option could be an empiric trial
with BASs. Cholestyramine is given for 10 days with a vari-
able dosage (4–36 g/day) [20]. In patients with symptom
improvement, the treatment may be stopped and, if the
BAM symptoms reappear after seven days, the test is consid-
ered positive. BAM diagnosis with a cholestyramine trial is









Figure 1: Venn diagram of diﬀerent causes of chronic diarrhea related to BAM.
2 Gastroenterology Research and Practice
is not supported by any quantitative data but only by the pres-
ence or the absence of a clinical improvement referred by the
patients. Moreover, evaluating the clinical response to BASs
may give false positive for a placebo eﬀect or false negative
for poor compliance with the therapy [21]. Furthermore,
the lack of speciﬁcity—since cholestyramine may inactivate
some diarrhea etiological agents such as the Clostridium diﬃ-
cile toxin [22, 23], the possible adverse events associated with
BASs (e.g., drug interactions), and the diﬃculty in determin-
ing the eﬀective dosage are not to be neglected.
4. The SeHCAT Test
The SeHCAT test, performed at the Nuclear Medicine
Department, is simple, fast, and well tolerated and requires
two scans one week apart. The SeHCAT test is the gold
standard for diagnosing BAM [24] because of its highest
sensitivity and speciﬁcity [25]; Merrick et al. [26] demon-
strated a sensitivity of 100% and a speciﬁcity of 91% with
a cutoﬀ value of 15%.
This test was ﬁrst performed in 1981 [27], and the proto-
col currently used was developed by Brydon et al. [16]. The
SeHCAT test is currently available in twelve European coun-
tries and in Canada, but not in the USA; it is relatively expen-
sive and it is usually available only at third-level centers. The
SeHCAT test measures the whole body retention of a radiola-
belled taurine-conjugated bile acid analogue (75Se) after
seven days; a retention value of ≤10–15% is usually consid-
ered diagnostic [1].
The standard patient preparation requires the suspension
of bile acid sequestrants and antidiarrheal drugs one week
prior to the ﬁrst appointment because of interference with
test results and requires fasting at least 4 hr before taking
the SeHCAT capsule (GE Healthcare).
The administered SeHCAT activity is very small
(370 kBq), with an eﬀective dose of radiation for an adult
of 0.26mSv and total absorbed radiation of 0.3Gy/kBq.
The absorbed dose for the small intestine and gallbladder
is 3.0 and 3.2Gy/kBq, respectively [28]. The absorbed dose
for the small bowel increases in patients who have under-
gone cholecystectomy and who have severe liver damage.
In comparison, the radiation dose given during an abdom-
inal CT scan is approximately 5.3mSv and the background
annual exposure in the UK is 1–3mSv [29].
The ﬁrst scan is usually performed 3hr after SeHCAT
capsule ingestion (370 kBq) while patients are still fasting.
The second scan is scheduled 7 days after capsule administra-
tion, which represents the optimal rescan time to calculate
the SeHCAT % retention and to diﬀerentiate the normal


















Figure 2: Pathophysiology of enterohepatic circulation: bile acids (BAs) excreted in the intestinal lumen are mainly reabsorbed in the ileum
through the apical sodium-dependent bile acid transporter (ASBT) and return to the liver through the portal vessels. Stimulation of the
farnesoid X receptor (FXR) initiates the production of ﬁbroblastic growth factor 15/19 (FGF-15/19) that interacts in the hepatocytes with
cholesterol 7 alpha-hydroxylase (CYP7A/1) and reduces BA synthesis, with a negative feedback mechanism. Mutations in ASBT and
klothoB have been demonstrated to be a cause of bile acid malabsorption (BAM).
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body’s retention of the radiotracer correlates with ileal
absorption [30].
There are diﬀerent gamma camera measurement
methods—whole-body count and static abdomen acquisition
with or without collimators (Figure 3). The total body or
abdominal acquisition is performed with the detector of the
gamma camera at the maximum opening of the gantry.
The abdominal acquisition is performed with patients in
a supine position in an uncollimated gamma camera and by
acquiring total counts in 5min, preceded or followed by a
background count acquisition either in the early (3 hr) or in
the late (7 days) scan with equal duration and position. Care
should be taken with abdominal acquisition, as it requires
identical patient positioning inside the camera between the
ﬁrst and the second scan [31].
Collimation removal improves test sensitivity and
accuracy, although, depending on the model of the gamma
camera, it may be necessary to pay attention to possible
crystal damage.
Abdominal counts are corrected for background (BG)
counts and for decay; 75-selenium has a relatively long
half-life (118 days). The percentage of abdominal (or
whole-body) retention is calculated according to the follow-
ing formula [32]:
Abdomen ANT 3 h Abdomen ANT 3 hAbdomen POST 3 h Abdomen POST 3 h
Abdomen ANT day 7 Abdomen ANT day 7Abdomen POST day 7 Abdomen POST day 7
Background ANT 3 h Background ANT 3 hBackground POST 3 h Background POST 3 h
Background ANT day 7 Background ANT day 7Background POST day 7 Background POST day 7
2140 kcounts 873 kcounts 3217 kcounts 1613 kcounts
41 kcounts 48 kcounts 42 kcounts 53 kcounts
1103 kcounts 562 kcounts 122 kcounts 116 kcounts
42 kcounts 50 kcounts 42 kcounts 54 kcounts
Figure 3: Examples of noncollimated abdomen images and related backgrounds at days 0 and 7 of a pathologic (a) and normal (b)
SeHCAT test.
% retention at day 7 = 1 04∗ Ant Counts day 7 −Ant BG counts ∗ Post Counts day 7 − Post BG counts
Ant Counts day 0 −Ant BG counts ∗ Post Counts day 0 − Post BG counts
∗100
1
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This method is used by many authors and gives a reliable
measure of SeHCAT retention. Figure 4 shows the 75-
selenium retention in a graphical format, which includes a
cutoﬀ line for abnormality for days 0–10.
The optimal cutoﬀ level to diagnose BAM varies from
≤10% to ≤15% [2]. Initially, a cutoﬀ value of ≤15% was
used, but later, in 1994, this value was revised to ≤10%
[33]. Considering a theoretical abnormal reabsorption of
bile acids of 94% in the enterohepatic circulation, on the
seventh day, the estimated cutoﬀ retention value would
be 10%. Therefore, it seems reasonable to consider this
the optimal cutoﬀ level [34]. In addition, Wedlake et al.
[1] observed that the response to cholestyramine was bet-
ter using 10% than using 15% as the cutoﬀ level (response
rate 80% vs. 70%, respectively).
Many studies classify BAD into mild, moderate, and
severe, on the basis of retention values on the seventh day
of ≤15%, ≤10%, and ≤5%, respectively [26, 33, 35–39]. A
recent review [25] shows the following percentages of
response to BAS therapy: mild BAM—73%, moderate
BAM—76%, and severe BAM—88%. BAM severity could
allow the clinician to predict the response to therapy and is
a starting point for evaluating clinical improvement.
Moreover, a positive diagnosis can have a positive psy-
chological impact on the patient, leading to a better compli-
ance with BAS therapy. Patients with a conﬁrmed diagnosis
are more motivated to start and continue a treatment with
BASs, which are not palatable and can potentially induce
some adverse events [40]. This is especially true for patients
with FD or IBS-D who have often undergone many diﬀerent
diagnostic tests. The diagnosis of BAM in patients with
chronic diarrhea has a great clinical relevance: since a
positive SeHCAT test does not exclude other organic causes
of diarrhea, patients should also undergo other tests as clini-
cally indicated. This is particularly true in patients treated
with many diﬀerent drugs, where the cause of diarrhea may
be diﬃcult to diagnose. The use of the SeHCAT test in these
instances may help in reaching the correct diagnosis. In an
open multicenter study [41] conducted in 98 IBS-D patients
who underwent the SeHCAT test, 56 patients showed altered
SeHCAT retention and 42 completed a course of cholestyr-
amine therapy at the mean dose of 4.8 g per day: only three
did not respond to the drug.
SeHCAT test enables the clinician to make a more rational
use of BASs which may induce adverse events. Prolonged BAS
treatment may lead to malabsorption of fats and liposoluble
vitamins (A, D, and K), increasing the risk of osteoporosis
and possible coagulation abnormalities. For this reason,
patients with coagulation defects or those taking oral anticoag-
ulant therapy should undergo a SeHCAT test to obtain a pre-
cise diagnosis and to evaluate the beneﬁt-risk ratio of BAS
administration, as well as patients assuming life-saving drugs
whose absorption could be potentially modiﬁed by BASs.
Despite the high percentage of patients with a positive
SeHCAT test responding to BASs, there are currently lim-
ited data on the duration and the dosage of the BAS ther-
apy and whether a clinical remission (negative SeHCAT
test) after a long-term BAS treatment is possible [33, 42].
5. Use of the SeHCAT Test in Patients with
Organic Diseases
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Figure 4: The lines show the threshold levels of the normal uptake value of SeHCAT from day 0 to day 10 evaluated for retention of 10% and
15% at day 7.
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5.1. Inﬂammatory Bowel Disease (IBD). In CD with ileal
involvement [43], BAM was diagnosed in 116/276 (42%)
patients; as expected, the most severe BAM was observed in
CD patients with more severe ileal involvement or after
resection of the distal ileum. It is common to ﬁnd CD
patients with persistent diarrhea despite having normal
inﬂammatory and disease activity indexes. BAM should be
suspected as a cofactor of diarrhea as IBS may coexist in
IBD patients [44]. A Dutch study highlighted that the major-
ity of IBD patients with IBS-type symptoms fulﬁlled the
criteria for IBS or mixed-type IBS [45]. Patients with CD
and unexplained persistent diarrhea without disease activity
should be screened for BAM [43] because therapeutic
response to BASs is related to BAM severity [35, 39, 46].
5.2. Neoplastic Disease and Postsurgical Patients.Gastrointes-
tinal symptoms are common consequences of many cancer
treatments and have great impact on a patient’s daily activi-
ties [47]. Diarrhea is one of the most frequent symptoms dur-
ing chemotherapy or radiotherapy, and BAM could be
involved in its pathophysiological mechanism [47].
In a study by Phillips et al. [13], 215 out of 506 (42.5%)
consecutive neoplastic patients treated with surgery, radio-
therapy, or chemotherapy and sent to a gastroenterological
evaluation for diarrhea reported a new diagnosis of BAM
with the SeHCAT test. It was mild in 25.6%, moderate in
29.3%, and severe in 45.1%. Since the adverse eﬀects of BASs
[37] (namely, interference with the absorption of micro-/
micronutrients and drugs) may be particularly dangerous in
these patients, a diagnosis of BAM should be carefully estab-
lished before starting BAS therapy, which could signiﬁcantly
improve symptoms and quality of life. A SeHCAT test scan
should be considered by the gastroenterologist treating can-
cer patients with diarrhea [13].
Up to 89% of the patients who have undergone Whip-
ple’s procedure may show a positive SeHCAT test [13]. In
these patients, BAM could occur because of the associated
vagotomy, which accelerates gut transit [48], but more prob-
ably it could be due to an alteration in bile production and/
or an overrapid intestinal transit, leading to malabsorption
of BAs. An interference from nonhydrolysed triglycerides,
which also impairs absorption, like in chronic pancreatitis
and pancreatic disease (i.e., cystic ﬁbrosis), could also be
possible [49, 50].
5.3. Cholecystectomy. BAM occurs in more than 90% of
patients with postcholecystectomy diarrhea (PCD) [51].
The pathophysiological mechanism is linked to the lack of
BA reservoir and the consequent inability of the gut to absorb
their excessive output. A study by Sciarretta et al. [51]
highlighted that patients with PCD responded favorably to
cholestyramine (2–12 g/day) and, in 60% of the cases, they
resolved their diarrhea after treatment withdrawal, despite
persistent evidence of BAM. In fact, some studies have shown
that BAS can improve diarrhea in many diﬀerent pathologi-
cal conditions, also in patients without BAM. In particular,
cholestyramine, which is a strong anion-exchange resin that
can bind with bacterial toxins and mycotoxins in the colon
[46], was eﬀective in improving diarrhea also in patients with
microscopic colitis without associated BAM, as reported by
Fernandez-Banares et al. [52]. It was also able to reduce the
risk of developing Clostridium diﬃcile-associated diarrhea
due to its capacity of binding to toxins A and B [22]. This
pharmacological eﬀect could work in the cholecystectomized
patient with a multifactorial diarrhea. This suggests the exis-
tence of other factors associated with BAM and, above all, a
healing role rather than a symptomatic one for this drug.
5.4. Habba Syndrome. This syndrome is deﬁned by the pres-
ence of abnormal gallbladder function and chronic postpran-
dial diarrhea responding to BASs [53]. Hepatobiliary nuclear
scintigraphy using Tc-99m-DISIDA with cholecystokinin
(DISIDA with CCK injection) has to be performed to esti-
mate the gallbladder ejection fraction, in accordance with
the standard calculation of gallbladder contraction 30
minutes after CCK injection, to establish the possible rela-
tionship of gallbladder dysfunction and chronic diarrhea.
An ejection fraction< 35% is considered grossly abnormal,
35–50% borderline abnormal, and >50% normal. The
response of the diarrhea to BASs is probably due to a
mechanism similar to that observed in PCD [51]. How-
ever, the poor function of the gallbladder seems to be
the common primary factor in this syndrome. The SeH-
CAT test can provide further diagnostic conﬁrmation,
and data on the response to BAS therapy have already
been discussed above.
6. Conclusions
The SeHCAT test is a safe and eﬀective method to diag-
nose BAM with high sensitivity and speciﬁcity. Table 1
summarizes the advantages and the disadvantages of the
SeHCAT test.
Due to the high prevalence of BAM in FD and IBS-D, the
SeHCAT test should be performed in chronic diarrhea with
functional characteristics after evaluating FBC, CRP, coeliac
Table 1: Advantages and disadvantages of the SeHCAT test for BAM.
Advantages Disadvantages
Gold standard for the diagnosis of BAM with high sensitivity and
speciﬁcity
Relatively expensive and usually available only at third-level centers
Simple, safe, and well tolerated SeHCAT does not exclude other causes of organic diarrhea
Quantitative evaluation of BAM predicts the response to therapy
with BASs
The optimal cutoﬀ level for diagnosis is not yet completely agreed by
all centers
More rational use of BASs in relation to possible side eﬀects Diagnosis of BAM could be empirically obtained with a BAS trial
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serology, thyroid function, and stool exams (calprotectin,
coproculture, ova, and parasites) [54, 55]. However, up
to now, its cost and the lack of an agreed standard cutoﬀ
have strongly limited its wider acceptance and availability
in everyday clinical practice. More widespread use of the
SeHCAT test should provide further information to help
understand the pathophysiologic mechanisms underlying
chronic diarrhea aﬄicting many diﬀerent patients and
ensure that they are oﬀered a treatment that is selected
on the basis of a reliable clinical test and not on simple
empirical observations.
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